Class: Nonnarcotic antitussive
- Suspension 30 mg per 5 mL
Centrally acting antitussive. Temporarily controls and suppresses the cough reflex by selectively depressing the medullary cough center.
Indications and Usage
Symptomatic relief of cough associated with the common cold, sinusitis, allergic rhinitis, and other upper respiratory tract conditions.
Newborns; breast-feeding mothers; hypersensitivity to any component of the product.
Dosage and AdministrationAdults and Children 12 yr of age and older
PO 30 to 60 mg (5 to 10 mL; 1 to 2 tsp) every 12 h.Children 6 to younger than 12 yr of age
PO 15 to 30 mg (2.5 to 5 mL; ½ to 1 tsp) every 12 h.Children 2 to younger than 6 yr of age
PO 7.5 to 15 mg (1.25 to 2.5 mL; ¼ to ½ tsp) every 12 h.
- Shake suspension well before measuring dose.
Store at 59° to 86°F. Protect from freezing.
Drug InteractionsCNS depressants (eg, alcohol, antihistamines, psychotropic drugs)
Additive CNS depressant effects may occur.MAOIs
Do not use in patients receiving MAOIs or within 14 days of stopping an MAOI.
Laboratory Test Interactions
None well documented.
Nausea and other GI disturbances.
Category C .
Safety and efficacy not determined in children younger than 2 yr of age.
Patients older than 60 yr of age are more likely to have adverse reactions.
Special Risk Patients
Use with caution in patients with CV disease, diabetes, hypertension, hyperthyroidism, narrow-angle glaucoma, or prostatic hypertrophy.
Product contains phenylalanine.
Central excitement and mental confusion. Patients older than 60 yr of age are more likely to experience CNS depression, convulsions, death, and hallucinations.
- Instruct patient to consult health care provider if cough persists for more than 1 wk, tends to recur, or is accompanied by a high fever, rash, or persistent headache.
- Advise patient to shake suspension well before administering dose.
- Advise phenylketonuria patients that this medication contains phenylalanine 7 mg per mL.